Skip to content

Safety and Efficacy of the EIP2 Irrigation System in Colorectal ESD: An Exploratory Study

An Exploratory Clinical Study on the Safety and Efficacy of an Irrigation System Linked to a High-Frequency Electrosurgical Device (EIP2) in Endoscopic Submucosal Dissection for Colorectal tumors

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1052250122
Enrollment
10
Registered
2025-09-29
Start date
2025-10-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal tumor Colorectal tumor

Interventions

Colorectal ESD is performed under water immersion by filling the intestinal lumen with saline irrigation. The ESD procedure consists of three steps: (1) submucosal injection, (2) circumferential incis
endoscopic submucosal dissection

Sponsors

Yoshizaki Tetsuya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Lesions eligible for ESD according to the Colorectal ESD/EMR Guidelines (2nd edition), meeting any of the following criteria: i) Lesions difficult to resect en bloc by snare EMR, including: LST-NG, especially the pseudo-depressed type Lesions with a type VI pit pattern T1 (SM) slightly invasive carcinoma Large depressed-type tumors Large elevated lesions suspected of carcinoma ii) Intramucosal tumors with submucosal fibrosis iii) Sporadic localized tumors arising in the background of chronic inflammation, such as ulcerative colitis iv) Local residual early carcinoma after prior endoscopic resection (2) Patients aged 18 years or older at the time of consent acquisition. (3) Patients who have provided written informed consent for participation in this clinical study based on their own free will.

Exclusion criteria

Exclusion criteria: (1) Patients who have previously been enrolled in this clinical study for a different lesion. (2) Patients on antithrombotic therapy who cannot discontinue their medication in accordance with the Endoscopy Guidelines for Antithrombotic Agents and its 2017 Supplement. (3) Patients with severe heart failure (NYHA class III or IV). (4) Other patients deemed inappropriate for inclusion by the investigators of this clinical study.

Design outcomes

Primary

MeasureTime frame
Time during which 30% of the endoscopic field is occupied by bubbles per discharge during immersion procedure

Secondary

MeasureTime frame
Procedure time (Time from the start of submucosal injection to the completion of lesion resection) Immersion procedure time (Duration of the procedure performed under water immersion) Whether or not to perform En bloc resection Whether or not to perform en bloc R0 resection (Lesion resected en bloc with negative resection margins) Number of discharges (Number of times the electrosurgical device was activated) Time during which 50% of the endoscopic field is occupied by bubbles Time during which 50% of the endoscopic field is occupied by bubbles per discharge during immersion procedure Time during which 30% of the endoscopic field is occupied by bubbles Time during which bubbles are present in the endoscopic field Time during which bubbles are present in the endoscopic field per discharge during immersion procedure Intraoperative perforation Delayed perforation Postoperative bleeding Post-ESD electrocoagulation syndrome Diarrhea Electrolyte imbalance

Contacts

Public ContactTetsuya Yoshizaki

Kobe University hospital

yoshizak@med.kobe-u.ac.jp+81-78-382-5774

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026